



KLARIA

Year-end report

Q4 2022

1 January–31 December 2022

**KLARIA PHARMA HOLDING AB (PUBL.)**

Year-end report January–December 2022

Successful rights issue brought 59.2 MSEK to Klaria

New collaboration agreement signed with PharmaMar

## Fourth quarter of 2022

- Net sales amounted to 2.2 MSEK (0.0 MSEK)
- Other income amounted to 0.2 MSEK (6.2 MSEK)
- R&D costs for the period amounted to 8.6 MSEK (28.1 MSEK)
- Profit after tax amounted to -12.9 MSEK (-24.8 MSEK)
- Earnings per share for the quarter amounted to -0.22 SEK (-0.48 SEK)
- Cash flow from operating activities amounted to -10.7 MSEK (-14.6 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 16.8 MSEK (25.5 MSEK)
- Equity as of December 31 amounted to 76.0 MSEK (69.4 MSEK)

## The period January-December 2021

- Net sales amounted to 5.9 MSEK (0.0 MSEK)
- Other income amounted to 0.7 MSEK (37.5 MSEK)
- R&D costs for the period amounted to 51.4 MSEK (63.5 MSEK)
- Profit after tax amounted to -63.8 MSEK (-53.5 MSEK)
- Earnings per share for the quarter amounted to -1.10 SEK (-1.03 SEK)
- Cash flow from operating activities amounted to -49.8 MSEK (-24.8 MSEK)
- Cash and cash equivalents in the parent company amounted to 15.5 MSEK (9.1 MSEK)
- Equity in the parent company amounted to 175.3 MSEK (158.4 MSEK)

## Retained earnings

The Board will propose to the Annual General Meeting to dispose of the results in the Parent Company so that

Share premium fund	192,374,094
<b>Ongoing new issue</b>	<b>34,683,956</b>
Profit/loss for the year	-53,575,255
<b>Total non-restricted equity</b>	<b>173,482,795</b>

the result for the year is balanced in a new account. After the proposed disposition, the unrestricted capital will amount to

Share premium reserve	173,482,795
<b>Total non-restricted equity</b>	<b>173,482,795</b>

## Summary of the financials

The Klaria Group TSEK (unless otherwise stated)	1 Oct-31 Dec		1 Jan-31 Dec	
	2022	2021	2022	2021
Net sales	2,209	0	5,868	0
Research and development costs	-8,609	-28,134	-51,356	-63,490
Profit after tax	-12,897	-24,827	-63,774	-53,534
Cash flow from operating activities	-10,666	-14,616	-49,759	-24,797
Cash and cash equivalents on the balance day*	16,761	25,491	16,761	25,491
Equity on the balance day	76,079	69,413	76,079	69,413

This Group interim report and year-end report was prepared in accordance with IAS 34 Interim Financial Reporting, the Swedish Annual Accounts Act (ÅRL) and IFRS as accepted by EU. For the parent company, the Swedish Annual Accounts Act (ÅRL) and Rådet för Finansiell Rapportering's (the Council for Financial Reporting) recommendation RFR 2 Accounting for Legal Entities was applied.

\* In January, an additional 19.5 MSEK was received in cash in the rights issue that was ongoing over the turn of the year.

## Significant events during the period

### **Collaboration initiated with PharmaMar regarding one-year study to develop clinical candidate**

On October 7, 2022, it was announced that Klaria has signed an agreement with the Spanish biopharmaceutical company PharmaMar with the aim of developing an Alginate film formulation of a PharmaMar substance. The research is expected to take about 1 year, with the goal being to develop an Alginate film that is ready for clinical development, a so-called clinical candidate. If the development of this formulation goes well, the parties intend to negotiate a license agreement that will give PharmaMar global rights to the product.

### **Decision to carry out a preferential rights issue**

On November 14, 2022, it was announced that the company's board decided to carry out a new issue of a maximum of 59,166,957 shares at a subscription price of 1.25 SEK per share with preferential rights for existing shareholders. The rights issue was approved at an extraordinary general meeting on November 30, 2022.

### **Marketing Authorization Application submitted for Sumatriptan Alginate Film in Europe**

On November 29, 2022, it was announced that Klaria has submitted a Marketing Authorization Application (MAA) for Sumatriptan Alginate Film for the treatment of migraine within the EU. Given that the validation is positive, Sumatriptan Alginate Film will proceed through the regulatory evaluation according to a normal time frame, which means that an approval could be obtained in the first quarter of 2024.

### **Klaria receives approx. 59.2 MSEK from the preferential rights issue**

On December 22, 2022, Klaria announced the outcome of the preferential rights issue that ended on December 21, 2022. The subscription summary shows that approximately 33.5 percent of the preferential issue was subscribed with and without the support of subscription rights, and thus the issue guarantors were awarded approximately 46.5 percent of the preferential issue. This means that Klaria will receive approximately 59.2 MSEK before issue costs.

## Significant events after the end of the period

### **New issued shares registered by the Swedish Companies Registration Office**

On January 20, 2023, it was announced that the preferential rights issue that ended on December 21, 2022 has been registered with the Swedish Companies Registration Office. The last day for trading in paid subscribed shares was Tuesday, January 24, 2023. The record date was Thursday, January 26, 2023, after which BTA's were converted into shares as of Monday, January 30, 2023.



## Klaria's CEO Jesper Wiklund comments

During the fourth quarter, two events with great importance for the company took place. On November 29, we submitted the application for market approval of Sumatriptan Alginate film for the treatment of migraine in the EU. This means that an approval can be obtained in the first quarter of 2024. The application for market approval for our first product is the single most important event to date in Klaria's history. We thus achieved the goal for what we have been working on in Klaria in recent years; clinical development, manufacturing and the regulatory processes. On December 22, we were able to announce that the outcome for our rights issue was 59 MSEK. Despite an extremely challenging stock and financing climate, we managed to end 2022 by successfully closing a financing round on good terms. With this financing, we were able to both strengthen our balance sheet and secure the capital we need for the operational activities in 2023.

The Marketing Authorization Application (MAA) for Sumatriptan Alginate Film for the treatment of migraine in the EU that we submitted in November was the final step in Klaria's journey towards approval of the product. We have now done everything we can to get Sumatriptan Alginate Film approved in Europe. The regulatory authorities will provide their decision in about 12 months. This means that we could have our first product on the market within a year. In order to secure a successful commercialization of Sumatriptan Alginate film in Europe, we want to collaborate with European pharmaceutical companies that focus on the treatment of pain and neurology.

We are also very pleased with our successful capital raising. The company has used approximately two thirds of the capital to strengthen the balance sheet by repaying loans. We now have approximately 16 MSEK left in loans from the lenders we have worked with in recent years. We were also able to secure attractive terms on the remaining loan, which further strengthens our financial position. It is also very important that we were able to welcome several new, strong and long-term shareholders in the company who participated in the rights issue.

Finally, our research and development work continued in the fourth quarter within the three research collaborations we have with our pharmaceutical company partners; Imbrium Therapeutics (Adrenaline Alginate Film), Fluimed (Sirolimus Alginate Film) and Pharmamar. As we conveyed in the last quarterly report, Klaria is now fully focused on researching together with paying partners in all our research. With this collaborative business model, our partners pay for the development of individual projects, and we continue to make progress across all three collaborations.

We look ahead into 2023 with a product on the way to market, a productive pipeline and a secured financial position. Our focus in 2023 is on securing commercialization partners for Sumatriptan Alginate Film and on continuing our research collaborations.

**Jesper Wiklund**

CEO of Klaria Pharma Holding AB (publ)  
Uppsala in February 2023



**“**Klaria's vision is to contribute to an improved quality of life for people with serious medical conditions by utilizing the company's unique Alginate Film technology.  
**”**



## Strategy

Klaria's strategy is to maximize shareholder value by focusing all of its development resources on projects where the current treatment fulfil two criteria: 1) the treatment is given as a nasal spray or injection due to weak or non-existing uptake in the stomach, and 2) this presents a significant problem for patients, caregivers or paying entities.

Klaria's existing projects for epinephrine (adrenaline) against acute allergic reaction is an excellent example of projects fulfilling both criteria.

Klaria's strategy utilizes the key feature of Alginate Films; true and full transmucosal drug delivery of pharmaceuticals with no uptake in the stomach. This differentiates Alginate Films from other oral transmucosal technologies such as starch based oral films, fast-dissolving tablets and oral sprays, where a significant portion of the active substance is mixed with saliva and swallowed, which creates a partly oral administration. In contrast to these technologies, Klaria's Alginate Films are able to deliver pharmaceuticals which are not orally available (i.e. uptake from the stomach/intestines to the blood stream is low or non-existent). This is why Klaria has been able to for example develop fully working transmucosal films for adrenaline. None of these drugs are orally available.

With this strategy, Klaria will be able to create substantial shareholder value by developing products which delivers an improved clinical outcome while also improving the user-friendliness compared to the products available on the market today.

The methodology of combining Klaria's patented drug delivery platform with well-known active substances brings great benefits to Klaria as a company, including shorter time to market, lower development costs and a reduced risk level compared to traditional drug development.

## Business model

Our strategy is conduct to research together with paying partners in all our research. We call this a "collaborative business model" with a focus on working together with partners who pay for the development of individual projects. This strategy is important to Klaria, as we see it as the best way for a drug development company with a technology platform to conduct research and development. Of the many advantages this strategy has, these are the three most important:

1. R&D becomes a source of income instead of a source of cost because the research is paid for by the partner. This means that we do not need to raise capital from our owners to pay for the research, instead we raise this capital directly from our partners or customers.
2. The company owns parts of all projects in the form of royalty or part ownership. Our long-term goal is to own a portfolio of valuable royalty streams from approved pharmaceuticals. With this model, we can get there with a minimum of risk and capital requirements, seen from our owners' perspective.
3. We only carry out projects where there is already strong interest from other pharmaceutical companies. It becomes a screening process at the very beginning of a project, as we must convince both researchers and commercial teams at a foreign pharmaceutical company to dedicate resources and capital to the project. This differs from the model many other biotech companies use, where they work alone for many years on a project and then try to identify a partner. This is a very risky process. The projects can fail, capital must be secured from investors and finally, even if everything goes well, it is difficult to know today what pharmaceutical companies might be interested in five or six years into the future.

## Klaria's operations cont.

### Klaria's drug delivery platform

Klaria's unique and patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa. The film is similar to a stamp and is attached to the inside of the cheek or palate. Within ten minutes, the active substance is distributed directly into the blood stream.

Klaria's Alginate Films offers several clear advantages to nasal sprays and injections:

- The convenient size makes the films easy to carry around, enabling a dramatic improvement in cases such as patients with severe allergies, who currently have to bring a large injector with them.
- Patients, caregivers and families do not have to worry about injections. Needle phobia is a widespread problem, in addition to the risks of using needles including spreading of infections.
- The dosage will be more precise compared to nasal spray as the substance takes a more direct route into the bloodstream. Any risk of the patient vomiting and losing the drug dose is eliminated.


### Patents

Klaria owns a patent portfolio that protects the unique Alginate technology behind the company's drug delivery platform. To further extend this protection, Klaria is continuously adding project-specific patent protection covering the combinations within each project. Up until now, the company has applied for such patent in all of its projects.

This enables Klaria to gradually build a strong patent portfolio, despite the fact that the active substances are well-known. Klaria now has approved patents for the platform covering all important markets in the world.






In January 2021, the company received the very positive decision from the US Patent Office USPTO that the product patent for Sumatriptan Alginate Film will be approved. The approval doubles the period of time during which Klaria's product is protected from generic copies and the price pressure it entails. The approval validates the company's patent strategy as it marks the second time the USPTO approves a specific product patent formulated in the company's Alginate Film.

“The film is similar to a stamp and is attached to the inside of the cheek or palate. Within ten minutes, the active substance is distributed directly into the bloodstream.”



## Pipeline for Klaria's development projects

- Collaboration based business model
- Focus where our technology solve unmet medical needs

	Pre-Clinical	Phase 1	Phase 2 / Phase 3	File for Approval	Partner
Sumatriptan	Completed	Completed	Completed	Ongoing	
Adrenaline/Epinephrine	Completed	Ongoing	Ongoing	Ongoing	
Sirolimus	Ongoing	Ongoing	Ongoing	Ongoing	
Undisclosed	Ongoing	Ongoing	Ongoing	Ongoing	
Medical Cannabis	Ongoing	Ongoing	Ongoing	Ongoing	

Explanation of the color coding: Completed Ongoing

### Sumatriptan

Klaria's Sumatriptan Alginate Film is a novel treatment for migraine. The film achieves transmucosal delivery of Sumatriptan, giving it unique and valuable benefits compared to any other currently available treatments. This is especially true for the 80 percent of migraine patients who suffer from nausea.

In 2018, Klaria received a grant of 21 MSEK in total from the innovation focused EU Horizon 2020 program. The most recent milestone payment was received in fourth quarter of 2021.

Klaria initiated a bioequivalence registration study in the fourth quarter of 2020, and positive results were presented in May 2021. Sumatriptan Alginate Film demonstrated both bioequivalence against two EU/US approved sumatriptan nasal spray products, and a reduced the inter-subject variability.

### Adrenaline/Epinephrine

Klaria's Adrenaline Alginate Film project aims to: 1. Replace EpiPen (aged incumbent technology with expensive and bulky auto-injector pen) with adrenaline/epinephrine formulated into Klaria's Alginate Film. 2. Disrupt the \$4.2 billion/year product EpiPen by offering a superior product with added value for the patient for the benefit of all patients. 3. Become the market leader. This potential makes Epinephrine Alginate Film a massive commercial opportunity for Klaria.

In March 2021, Klaria signed an option agreement with Imbrium Therapeutics for the US marketing rights of Epinephrine Alginate Film. Should Imbrium exercise its option after completion of clinical studies by Klaria, Klaria will be eligible to receive USD 66,5 million (SEK 560 million) in milestone payments as well as a double-digit royalty on the United States net sales.



## Klaria's operations, cont.

### Cannabis Delivery Sciences

The mission of Cannabis Delivery Sciences (CDS) is to fully realize the commercial opportunities of cannabis/cannabinoids, including THC and CBD, in Klaria's unique film technology. CDS is a separate entity operating within the Klaria group, with a focus on both medical and recreational applications. So far, the company has signed three agreements for the commercialization of cannabinoids in Klaria's film technology followed by sales as a part of each partner's product portfolio: with Chilam Enterprise Ltd, with Pure Jamaican Limited, and with Hemply Balance. More information is available on CDS's website, [www.cannabisdeliverysciences.com](http://www.cannabisdeliverysciences.com).

#### Cannabis Delivery Sciences enables:

- An entirely new, patent protected category of cannabis products with a rapid and exact uptake of cannabinoids (effect after approx. 20 minutes), without the social/health related drawbacks of smoking and edibles.
- Dedicated resources with focus to sign agreements with strong entities on the cannabis market.
- Utilisation of a team with extensive marketing experience in several regions including the United States, Canada, Jamaica and the United Kingdom.

#### A fast-growing market worth over 30 billion USD by 2022

The total cannabis market is estimated to be worth 30 billion USD by 2020. Cannabis edibles (oils, drinks, cookies and gummies) constitute one of the segments and is expected to be worth over 4 billion USD in 2022. Absorption via edibles is however inexact, and time to effect is usually over one hour.

The smoking segment has an estimated value of over 20 billion USD, but is associated with significant health and regulatory disadvantages.

Cannabis Delivery Sciences expects that it will reach a significant market share in both these segments. Klaria's film technology is easier to use and carry, provides more accurate dosing and allows significantly shorter time to effect compared to edible products. At the same time, the technology is free of the health and regulatory disadvantages associated with smoking.

“Cannabis Delivery Sciences enables full realization of the commercial opportunities of cannabis products formulated in Klaria's unique film technology.



## Financial development in summary

The Klaria Group TSEK (unless otherwise stated)	1 Oct-31 Dec		1 Jan-31 Dec	
	2022	2021	2022	2021
Net sales	2,209	0	5,868	0
Other operating income	233	6,172	669	37,519
Operating Costs	-11,759	-31,100	-61,511	-87,628
Research and development costs	-8,609	-28,134	-51,356	-63,490
Operating profit/loss	-9,317	-24,928	-54,974	-50,109
Profit/loss after financial items	-12,808	-24,827	-63,657	-53,545
Profit/loss after tax	-12,897	-24,827	-63,774	-53,534
Cash flow from operating activities	-10,666	-14,616	-49,759	-24,797
Cash and cash equivalents on the balance day	16,761	25,491	16,761	25,491
Equity on the balance day	76,079	69,413	76,079	69,413
<b>Financial summary</b>				
Return on equity, %	neg	neg	neg	neg
Return on capital employed, %	neg	neg	neg	neg
Earnings per share, before and after dilution, SEK	-0.22	-0.48	-1.10	-1.03
Equity/assets ratio	63%	59%	63%	59%
Equity per share, SEK	0.97	1.34	0.97	1.34
Cash flow from operating activities per share, SEK	-0.18	-0.28	-0.86	-0.48
Number of employees at the end of the period	6	6	6	6

## Fourth quarter, October-December

### Net sales

The Group's net sales for the quarter amounted to 2,209 TSEK (0 TSEK).

### Costs

Costs during the quarter amounted to 11,759 TSEK (31,100 TSEK), divided into administrative costs of 2,380 TSEK (2,191 TSEK), sales costs of 770 TSEK (775 TSEK) and research and development costs of 8,609 TSEK (28,134 TSEK).

### Earnings

Profit/loss after financial items and net profit after tax was -12,897 TSEK (24,827 TSEK), or -0.22 SEK (-0.48 SEK) per share.

### Cash flow and liquidity

The cash flow for the quarter amounted to 10,017 TSEK (-374 TSEK) thanks to the liquid part of the new issue that came in during December with 20,934 TSEK. The cash flow from operating activities amounted to -10,666 TSEK (-14,616 TSEK) or -0.18 SEK (-0.28 SEK) per share. Klaria's liquidity at the end of the period was 16,761 TSEK (25,491 TSEK).

### Investments

During the quarter, Klaria has invested 0 TSEK (0 TSEK) in tangible fixed assets.

### Equity

At the end of the period, the Klaria Group's equity amounted to 76,079 TSEK (69,413 TSEK) or 0.97 SEK (1.34 SEK) per share. Equity increased by 49,637 TSEK after issue expenses thanks to the issue that was completed in December. Equity/assets ratio was 63% (59%) at the end of the period.

## The period January-December

### Net sales

The Group's net sales for the period amounted to 5,868 TSEK (0 TSEK).

### Costs

Costs during the quarter amounted to 61,511 TSEK (87,628 TSEK), divided into administrative costs of 7,862 TSEK (7,546 TSEK), sales costs of 2,293 TSEK (2,309 TSEK) and research and development costs of 51,356 TSEK (63,490 TSEK). Other operating expenses 0 TSEK (14,283 TSEK). During the quarter last year, an additional purchase price of 14,283 TSEK was

paid to FFT Medical AB for the acquisition of Uppsalagruppen AB, partly in cash 1,000 TSEK and partly through a directed new issue of 2,158,678 shares to FFT Medical AB. The additional purchase price is expensed according to IFRS accounting practice.

### Earnings

Profit/loss after financial items and net profit after tax was -63,774 TSEK (-53,534 TSEK), or -1.10 SEK (-1.03 SEK) per share.

### Cash flow and liquidity

The cash flow for the quarter amounted to -8,745 TSEK (5,759 TSEK), and the cash flow from operating activities amounted to -49,759 TSEK (-24,797 TSEK) or -0.86 SEK (-0.48 SEK) per share. In January, an additional 19.5 MSEK was received in cash in the rights issue that was ongoing over the turn of the year.

### Investments

During the quarter, Klaria has invested 42 TSEK (0 TSEK) in tangible fixed assets.

### Fiscal deficits

Klaria's current operations are initially expected to generate negative earnings and fiscal deficits. There are currently not convincing enough reasons to indicate fiscal surpluses in the future that can justify capitalisation of the value of loss carry-forwards. Deferred tax assets have therefore not been reported. Sales of a candidate drug are expected to generate profits which at present are estimated to be taxdeductible from previous years' fiscal deficits, which would entail a low tax burden on the Company when a project is sold or the pharmaceutical is launched on a commercial market. The fiscal deficits for the Group companies amounted to 141,207 TSEK per December 31, 2021 and amounted to 194,573 TSEK per December 31, 2022.

### Personnel

The number of employees at the end of the period was 6 (incl. CEO). Several functions in the company are staffed by consultants, engaged part-time with long-term contracts.

### The parent company

The legal form of the company is a public limited liability company, regulated by the Swedish Companies' Act (2005:551). The Board's registered office is located in Stockholm. Klaria Pharma Holding AB (publ) is the parent company in a group of nine companies in total. Klaria Pharma Holding AB owns all shares in Klaria Incentive AB (559084-7793), Uppsalagruppen

Medical AB (556847-3390), WBC Drug Delivery Technologies GmbH AG Munich (HRB 247378), Karessa Pharma AB (556966-7420), Karessa Incentive AB (559084-7793), Klaria AB (559012-2577), which in turn owns all shares in FFT Pharmaceutical AB (556955-6573). Furthermore, Klaria Pharma Holding AB (publ) owns 95% of CDS Functional Film AB (559222-7374).

## Fourth quarter October-December

Net sales in the parent company during the quarter amounted to 0 TSEK (0 TSEK). Costs amounted to 6,812 TSEK (18,199 TSEK), of which administration costs amounted to 4,076 TSEK (2,455 TSEK), sales costs to 593 TSEK (409 TSEK) and research and development costs to 2,143 TSEK (1,052 TSEK). Profit after net financial items for the quarter was -8,849 TSEK (-16,804 TSEK). Other operating expenses were 0 TSEK (14,283 TSEK). During the same quarter last year, an additional purchase price of 14,283 TSEK was paid to FFT Medical AB for the acquisition of Uppsalagruppen AB, partly in cash (1,000 TSEK) and partly through a directed new issue of 2,158,678 shares to FFT Medical AB. The additional purchase price is expensed according to IFRS accounting practice.

Liquidity in the parent company per December 31, 2022 was 15,513 TSEK (9,122 TSEK). Equity at the end of the period amounted to 175,257 TSEK (158,393 TSEK) and the equity/assets ratio was 78% (81%).

## Share capital

As of December 31, Klaria's share capital amounts to 1,306,356.62 SEK divided between 78,378,396 outstanding shares after partial registration of 19,211,439 shares and share capital of 320,190.96 SEK with the Swedish Companies Registration Office on December 28, 2022. The new share issue completed in December brought in 59,167 TSEK in total, of which 20,934 TSEK affected liquidity in December 2022. Remaining payment of 19,519 TSEK was received in January 2023 after 15,634 TSEK was offset against loans. The number of shares registered with the Swedish Companies Registration Office after the issue as per 18-01-2023 is 106,500,523, and the share capital amounts to 1,775,008.72 SEK.

## The share

Klaria Pharma Holding's share is listed on First North under the short name KLAR with ISIN code SE0005506193. Klaria's ICB category is Subsector 4577. FNCA Sweden AB is the company's Certified Advisor. As of December 31 2022, the number of shareholders in the company amounted to approximately 5,100.

## The period January-December

Net sales in the parent company during the period amounted to 0 TSEK (0 TSEK). The costs amounted to 18,702 TSEK (29,507 TSEK), of which administration costs constituted 11,190 TSEK (9,740 TSEK), sales costs 1,660 TSEK (1,347 TSEK) and research and development costs 5,852 TSEK (4,137 TSEK). Profit after net financial items for the period was -21,755 TSEK (-27,810 TSEK). As of 31 December, the parent company has provided group contributions to subsidiaries of 31,820 TSEK (15,285 TSEK).

## Significant risks and uncertainties

Through its operations, Klaria is exposed to risks and uncertainties. Information about the company's risks and uncertainties can be found on pages 28-29 in the company's annual report for 2021, which is available on the company's website: [www.klaria.com](http://www.klaria.com).



## Consolidated income statement (Group)

The Klaria Group TSEK (unless otherwise stated)	1 Oct-31 Dec		1 Jan-31 Dec	
	2022	2021	2022	2021
<i>Operating revenues</i>				
Net sales	2,209	0	5,868	0
Other operating revenues	233	6,172	669	37,519
<b>Total operating revenues</b>	<b>2,442</b>	<b>6,172</b>	<b>6,537</b>	<b>37,519</b>
<i>Operating costs</i>				
Administrative costs	-2,380	-2,191	-7,862	-7,546
Sales costs	-770	-775	-2,293	-2,309
Research and development costs	-8,609	-28,134	-51,356	-63,490
Other operating costs	0	0	0	-14,283
<b>Total operating costs</b>	<b>-11,759</b>	<b>-31,100</b>	<b>-61,511</b>	<b>-87,628</b>
<b>Operating profit/loss</b>	<b>-9,317</b>	<b>-24,928</b>	<b>-54,974</b>	<b>-50,109</b>
<i>Earnings from financial investments</i>				
Net interest income	-3,491	101	-8,683	-3,436
<b>Profit/loss after financial items</b>	<b>-12,808</b>	<b>-24,827</b>	<b>-63,657</b>	<b>-53,545</b>
Tax	-89	0	-117	11
<b>Profit/loss for the period</b>	<b>-12,897</b>	<b>-24,827</b>	<b>-63,774</b>	<b>-53,534</b>
Attributable to parent company shareholders	-12,897	-24,827	-63,774	-53,534
Of which the minority's share	0	0	0	0
Average number of shares before and after dilution (thousands)	59,594	51,808	58,102	51,808
Number of shares on the balance day (thousands)	78,378	51,808	78,378	51,808
Profit/loss per share before and after dilution, SEK	-0.22	-0.48	-1.10	-1.03

## Consolidated income statement

TSEK (unless otherwise stated)	1 Oct-31 Dec		1 Jan-31 Dec	
	2022	2021	2022	2021
Earnings for the period	-12,897	-24,827	-63,774	-53,534
Other earnings in total for the period, net before tax	27	-8	1	-2
<b>Earnings in total for the period</b>	<b>-12,870</b>	<b>-24,835</b>	<b>-63,773</b>	<b>-53,536</b>
Attributable to parent company shareholders	-12,870	-24,835	-63,773	-53,536
Minority interest	0	0	0	1

## Consolidated balance sheet (Group)

The Klaria Group TSEK (unless otherwise stated)	31 Dec	
	2022	2021
<i>Assets</i>		
<i>Non-current assets</i>		
<i>Intangible assets</i>		
Intellectual property rights	78,445	88,785
<i>Tangible assets</i>		
Machinery and equipment	35	0
<i>Financial assets</i>		
Right-of-use	1,033	1,721
<b>Total non-current assets</b>	<b>79,513</b>	<b>90,506</b>
<i>Current assets</i>		
Accounts receivable and other receivables	23,996	2,312
Cash and cash equivalents	16,761	25,491
<b>Total current assets</b>	<b>40,757</b>	<b>27,803</b>
<b>Total assets</b>	<b>120,270</b>	<b>118,309</b>
<i>Equity and liabilities</i>		
<i>Equity</i>		
<b>Total equity</b>	<b>76,079</b>	<b>69,413</b>
Minority interest in subsidiaries	2	2
<i>Provisions and liabilities</i>		
Non-current liabilities	342	1,020
Current liabilities	43,847	47,874
<b>Total provisions and liabilities</b>	<b>44,189</b>	<b>48,894</b>
<b>Total equity and liabilities</b>	<b>120,270</b>	<b>118,309</b>

## Changes in equity (Group)

The Klaria Group, 1 Jan 2021–31 Dec 2021

TSEK (unless otherwise stated)	Share capital	Ongoing new issue	Other contributed capital	Translation reserve	Accumulated loss	Minority share of equity	Total equity
Opening balance 2021-01-01	863		273,661	-22	-164,909	-2	109,591
<i>Comprehensive income</i>							
Income for the period				-1	-53,534		-53,535
<b>Total comprehensive income</b>	<b>0</b>			<b>-1</b>	<b>-53,534</b>	<b>0</b>	<b>-53,535</b>
<i>Transactions with shareholders</i>							
							0
New issue expenses			38				38
Ongoing new issue		13,319					13,319
<b>Total transactions with shareholders</b>	<b>0</b>	<b>13,319</b>	<b>38</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>13,357</b>
<b>Closing balance 2021-12-31</b>	<b>863</b>	<b>13,319</b>	<b>273,699</b>	<b>-23</b>	<b>-218,443</b>	<b>-2</b>	<b>69,413</b>
Opening balance 2021-10-01	863		273,701	-17	-179,354	-2	95,191
<i>Comprehensive income</i>							
Income for the period				-6	-39,089		-39,095
<b>Total comprehensive income</b>	<b>0</b>		<b>0</b>	<b>-6</b>	<b>-39,089</b>		<b>-39,095</b>
<i>Transactions with shareholders</i>							
							0
New issue expenses			-2				-2
Ongoing new issue		13,319					13,319
<b>Total transactions with shareholders</b>	<b>0</b>	<b>13,319</b>	<b>-2</b>	<b>0</b>	<b>0</b>		<b>13,317</b>
<b>Closing balance 2021-12-31</b>	<b>863</b>	<b>13,319</b>	<b>273,699</b>	<b>-23</b>	<b>-218,443</b>	<b>-2</b>	<b>69,413</b>



## Changes in equity (Group)

The Klaria Group, 1 Jan 2022–31 Dec 2022

TSEK (unless otherwise stated)	Share capital	Ongoing new issue	Other contributed capital	Translation reserve	Accumulated loss	Minority share of equity	Total equity
Opening balance 2022-01-01	863	13,319	273,699	-23	-218,443	-2	69,413
<i>Comprehensive income</i>							
Disposition of previous year's results			-53,534	0	53,534		0
Income for the period				1	-63,774		-63,773
<b>Total comprehensive income</b>	<b>0</b>		<b>-53,534</b>	<b>1</b>	<b>-10,240</b>	<b>0</b>	<b>-63,773</b>
<i>Transactions with shareholders</i>							
Adjustment of the previous year's ongoing new issue		-13,319					-13,319
Issue expenses	443	35,153	57,689				93,285
Total transactions with shareholders		-9,527					-9,527
<b>Closing balance 2022-12-31</b>	<b>443</b>	<b>12,307</b>	<b>57,689</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>70,439</b>
Opening balance 2022-10-01	1,306	25,626	331,388	-22	-282,217	-2	76,079
<i>Comprehensive income</i>							
Comprehensive income	986		307,697	-49	-269,320	-2	39,312
<i>Income for the period</i>							
Total comprehensive income				27	-12,897		-12,870
<b>Transactions with shareholders</b>	<b>0</b>		<b>0</b>	<b>27</b>	<b>-12,897</b>	<b>0</b>	<b>-12,870</b>
<i>New share issues</i>							
Issue expenses	320	35,153	23,691				59,164
Total transactions with shareholders		-9,527					-9,527
<b>Total transactions with shareholders</b>	<b>320</b>	<b>25,626</b>	<b>23,691</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>49,637</b>
<b>Closing balance 2022-12-31</b>	<b>1,306</b>	<b>25,626</b>	<b>331,388</b>	<b>-22</b>	<b>-282,217</b>	<b>-2</b>	<b>76,079</b>

## Consolidated cash flow statement (Group)

The Klargia Group TSEK (unless otherwise stated)	1 Oct-31 Dec		1 Jan-31 Dec	
	2022	2021	2022	2021
<i>Operating activities</i>				
Operating profit/loss after financial items	-12,896	-39,110	-63,774	-53,545
Depreciation	3,791	2,802	11,034	10,965
Other items not affecting cash flow	0	13,283	0	13,283
Taxes paid	-133	11	-133	11
<b>Cash flow from operating activities before changes in working capital</b>	<b>-9,238</b>	<b>-23,014</b>	<b>-52,873</b>	<b>-29,286</b>
Changes in working capital	-1,428	8,398	3,114	4,489
<b>Cash flow from operating activities</b>	<b>-10,666</b>	<b>-14,616</b>	<b>-49,759</b>	<b>-24,797</b>
<i>Investment activities</i>				
Acquisition of subsidiaries, net liquidity impact	0	0	0	0
Investments in tangible fixed assets	0	0	-42	0
<b>Cash flow from investing activities</b>	<b>0</b>	<b>0</b>	<b>-42</b>	<b>0</b>
<b>Cash flow before financing activities</b>	<b>-10,666</b>	<b>-14,616</b>	<b>-49,801</b>	<b>-24,797</b>
<i>Financing activities</i>				
Borrowings	0	15,045	0	20,045
Amortization of loans	0		0	
Liabilities attributable to financing activities	-551	-841	-678	-1,045
Contributed capital	21,234	38	41,734	38
<b>Cash flow from financing activities</b>	<b>20,683</b>	<b>14,242</b>	<b>41,056</b>	<b>19,038</b>
<b>Cash flow for the period</b>	<b>10,017</b>	<b>-374</b>	<b>-8,745</b>	<b>-5,759</b>
Cash and cash equivalents, opening balance	6,725	25,866	25,491	31,251
Exchange rate differences in cash and cash equivalents	-19	1	-15	1
Cash and cash equivalents, closing balance	16,761	25,491	16,761	25,491

## Income statement (parent company)

TSEK (unless otherwise stated)	1 Oct-31 Dec		1 Jan-31 Dec	
	2022	2021	2022	2021
<i>Operating income</i>				
Net sales	0	0	0	0
Other operating income	1,303	1,222	4,990	4,897
<i>Operating costs</i>				
Administrative costs	-4,076	-2,455	-11,190	-9,740
Sales costs	-593	-409	-1,660	-1,347
Research and development costs	-2,143	-1,052	-5,852	-4,137
Other operating costs	0	-14,283	0	-14,283
<b>Total operating costs</b>	<b>-6,812</b>	<b>-18,199</b>	<b>-18,702</b>	<b>-29,507</b>
<b>Operating profit/loss</b>	<b>-5,509</b>	<b>-16,977</b>	<b>-13,712</b>	<b>-24,610</b>
<i>Earnings from financial investments</i>				
Net interest income	-3,340	173	-8,043	-3,200
<b>Profit/loss after financial items</b>	<b>-8,849</b>	<b>-16,804</b>	<b>-21,755</b>	<b>-27,810</b>
Appropriations	-31,820	-15,285	-31,820	-15,285
Tax	0	0	0	0
<b>Profit/loss for the period</b>	<b>-40,669</b>	<b>-32,089</b>	<b>-53,575</b>	<b>-43,095</b>



## Balance sheet (parent company)

TSEK (unless otherwise stated)	31 Dec	
	2022	2021
<i>Assets</i>		
<i>Non-current assets</i>		
<i>Tangible assets</i>		
Equipment	35	0
<i>Financial assets</i>		
Participations in subsidiaries	178,339	178,339
<b>Total non-current assets</b>	<b>178,374</b>	<b>178,339</b>
<i>Current assets</i>		
Receivables from group companies	10,050	7,896
Accounts receivable and other receivables	20,605	410
Cash and cash equivalents	15,513	9,122
<b>Total current assets</b>	<b>45,525</b>	<b>17,428</b>
<b>Total assets</b>	<b>223,899</b>	<b>195,767</b>
<i>Equity and liabilities</i>		
<i>Equity</i>		
Restricted equity	1,775	14,182
Non-restricted equity	173,482	144,211
<b>Total equity</b>	<b>175,257</b>	<b>158,393</b>
<i>Provisions and liabilities</i>		
Liabilities to group companies	12,610	1,430
Current liabilities	36,032	35,944
<b>Total provisions and liabilities</b>	<b>48,642</b>	<b>37,374</b>
<b>Total equity and liabilities</b>	<b>223,899</b>	<b>195,767</b>

## Note 1 Accounting Policies

Consolidated accounts for Klaria Pharma Holding AB have been prepared in accordance with International Financial Reporting Standards (IFRS) as they have been adopted by the EU, the Annual Accounts Act (ÅRL) and the Swedish Financial Reporting Council RFR 1 Supplementary accounting rules for groups. The parent company's financial reports are prepared in accordance with the Annual Accounts Act and RFR 2 Accounting for legal entities. The year-end report is prepared in accordance with IAS 34 Interim reporting and the Annual Accounts Act. Information according to IAS 34 is provided both in the notes and elsewhere in the year-end report. The accounting principles and calculation methods applied are in accordance with those described in the annual report for 2021.

## Note 2 Transactions with related parties

No transactions with related parties have been made during the quarter or the period.

## Profit/loss per share

Net profit/loss divided by the average number of shares.

## Average number of shares

The average number of shares in Klaria Pharma Holding AB (publ) has been calculated on the basis of a weighting of the historical number of issued shares in Klaria Pharma Holding AB (publ) after each completed share issue, times the number of days since the respective number of shares were issued.

## Equity/assets ratio

Equity in relation to total assets.

## Return on equity

Profit/loss after tax.

## Return on capital employed

Profit/loss after net interest income in relation to capital employed.

## Capital employed

Total assets minus interest-bearing liabilities.

## Equity per share

Equity divided by the number of shares on the balance day.

## Cash flow from operating activities per share

Cash flow from operating activities divided with the average number of shares.

## Cash flow per share

Cash flow for the period divided with the average number of shares.





The interim and year-end report have been reviewed by the auditors. The Board of Directors and CEO hereby assure that this interim and year-end report gives a true and fair view of the company's operations, financial position and performance.

Stockholm 2023-02-10

## The Board of Directors

**Fredrik Hübinette**  
Chairman of the Board

**Anders Jacobson**  
Director of the Board

**Scott Boyer**  
Director of the Board

**Jesper Wiklund**  
CEO

This interim report has not been reviewed by the company's auditors.

This information is such information that Klaria Pharma Holding AB (publ) is obligated to publish in compliance with the EU market abuse regulation and the Securities Markets Act. The information was provided, through the contact set out on page 12, for publication on February 10 2023 at 08.30 CET.



# Financial calendar

Interim report 2022	2023-04-07
Annual general meeting	2023-05-12
Interim report Q1	2023-05-26
Interim report Q2	2023-08-25
Interim report Q3	2023-11-24
Year-end report 2023	2024-02-23

For further information, please contact:

Jesper Wiklund

+49 176 342 962 77

jesper.wiklund@klaria.com

Klaria Pharma Holding AB (publ)

Virdings Allé 2

754 50 UPPSALA, SWEDEN

[www.klaria.com](http://www.klaria.com)





# KLARIA

**KLARIA PHARMA HOLDING AB (PUBL.)**

Year-end report January–December 2022